AbbVie Reports First-Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
AbbVie (ABBV) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
April 29, 2026 7:48 AM EDTAbbVie (NYSE: ABBV) reported Q1 EPS of $2.65, $0.06 better than the analyst estimate of $2.59. Revenue for the quarter came in at $15 billion versus the consensus estimate of $14.73 billion.
GUIDANCE:
AbbVie sees FY2026 EPS of $14.08-$14.28, versus the consensus of $14.21.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More